NL8001000A - Werkwijzen voor het bereiden van een geneesmiddel tegen hypertensie en voor het behandelen van hypertensie daarmede. - Google Patents
Werkwijzen voor het bereiden van een geneesmiddel tegen hypertensie en voor het behandelen van hypertensie daarmede. Download PDFInfo
- Publication number
- NL8001000A NL8001000A NL8001000A NL8001000A NL8001000A NL 8001000 A NL8001000 A NL 8001000A NL 8001000 A NL8001000 A NL 8001000A NL 8001000 A NL8001000 A NL 8001000A NL 8001000 A NL8001000 A NL 8001000A
- Authority
- NL
- Netherlands
- Prior art keywords
- active ingredients
- process according
- weight ratio
- hypertension
- endralazine
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 30
- 206010020772 Hypertension Diseases 0.000 title description 7
- 239000004480 active ingredient Substances 0.000 claims description 35
- 230000000054 salidiuretic effect Effects 0.000 claims description 15
- LBXHRAWDUMTPSE-AOOOYVTPSA-N 4-chloro-N-[(2S,6R)-2,6-dimethyl-1-piperidinyl]-3-sulfamoylbenzamide Chemical compound C[C@H]1CCC[C@@H](C)N1NC(=O)C1=CC=C(Cl)C(S(N)(=O)=O)=C1 LBXHRAWDUMTPSE-AOOOYVTPSA-N 0.000 claims description 14
- 229960004070 clopamide Drugs 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 13
- ALAXZYHFVBSJKZ-UHFFFAOYSA-N endralazine Chemical compound C1CC=2N=NC(NN)=CC=2CN1C(=O)C1=CC=CC=C1 ALAXZYHFVBSJKZ-UHFFFAOYSA-N 0.000 claims description 12
- 229960002029 endralazine Drugs 0.000 claims description 12
- 229960002508 pindolol Drugs 0.000 claims description 10
- 206010020852 Hypertonia Diseases 0.000 claims description 7
- AQCHWTWZEMGIFD-UHFFFAOYSA-N metolazone Chemical compound CC1NC2=CC(Cl)=C(S(N)(=O)=O)C=C2C(=O)N1C1=CC=CC=C1C AQCHWTWZEMGIFD-UHFFFAOYSA-N 0.000 claims description 7
- 229960002817 metolazone Drugs 0.000 claims description 7
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 6
- 229960002003 hydrochlorothiazide Drugs 0.000 claims description 5
- 150000003839 salts Chemical group 0.000 claims description 5
- 239000002220 antihypertensive agent Substances 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 3
- 229940127088 antihypertensive drug Drugs 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims 2
- 239000000969 carrier Substances 0.000 claims 1
- PHUTUTUABXHXLW-UHFFFAOYSA-N pindolol Chemical compound CC(C)NCC(O)COC1=CC=CC2=NC=C[C]12 PHUTUTUABXHXLW-UHFFFAOYSA-N 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 description 12
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 10
- JZQKKSLKJUAGIC-UHFFFAOYSA-N pindolol Chemical compound CC(C)NCC(O)COC1=CC=CC2=C1C=CN2 JZQKKSLKJUAGIC-UHFFFAOYSA-N 0.000 description 10
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 229920002261 Corn starch Polymers 0.000 description 5
- 239000008120 corn starch Substances 0.000 description 5
- 235000019359 magnesium stearate Nutrition 0.000 description 5
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 230000002349 favourable effect Effects 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- SSEAPVMQZPKNQZ-UHFFFAOYSA-N 2-(aminomethyl)-4-tert-butyl-6-iodophenol Chemical compound CC(C)(C)C1=CC(I)=C(O)C(CN)=C1 SSEAPVMQZPKNQZ-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 230000003276 anti-hypertensive effect Effects 0.000 description 2
- 229940030600 antihypertensive agent Drugs 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- -1 granulants Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000000810 peripheral vasodilating agent Substances 0.000 description 2
- 229960002116 peripheral vasodilator Drugs 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- WCOXQTXVACYMLM-UHFFFAOYSA-N 2,3-bis(12-hydroxyoctadecanoyloxy)propyl 12-hydroxyoctadecanoate Chemical class CCCCCCC(O)CCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC(O)CCCCCC)COC(=O)CCCCCCCCCCC(O)CCCCCC WCOXQTXVACYMLM-UHFFFAOYSA-N 0.000 description 1
- FHQAWINGVCDTTG-UHFFFAOYSA-N 4-chloro-3-sulfamoylbenzoic acid Chemical compound NS(=O)(=O)C1=CC(C(O)=O)=CC=C1Cl FHQAWINGVCDTTG-UHFFFAOYSA-N 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- CESYKOGBSMNBPD-UHFFFAOYSA-N Methyclothiazide Chemical compound ClC1=C(S(N)(=O)=O)C=C2S(=O)(=O)N(C)C(CCl)NC2=C1 CESYKOGBSMNBPD-UHFFFAOYSA-N 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- CYLWJCABXYDINA-UHFFFAOYSA-N Polythiazide Polymers ClC1=C(S(N)(=O)=O)C=C2S(=O)(=O)N(C)C(CSCC(F)(F)F)NC2=C1 CYLWJCABXYDINA-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 229960003515 bendroflumethiazide Drugs 0.000 description 1
- HDWIHXWEUNVBIY-UHFFFAOYSA-N bendroflumethiazidum Chemical compound C1=C(C(F)(F)F)C(S(=O)(=O)N)=CC(S(N2)(=O)=O)=C1NC2CC1=CC=CC=C1 HDWIHXWEUNVBIY-UHFFFAOYSA-N 0.000 description 1
- 229960001541 benzthiazide Drugs 0.000 description 1
- NDTSRXAMMQDVSW-UHFFFAOYSA-N benzthiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(S(N2)(=O)=O)=C1N=C2CSCC1=CC=CC=C1 NDTSRXAMMQDVSW-UHFFFAOYSA-N 0.000 description 1
- 102000015005 beta-adrenergic receptor activity proteins Human genes 0.000 description 1
- 108040006818 beta-adrenergic receptor activity proteins Proteins 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229960002155 chlorothiazide Drugs 0.000 description 1
- JIVPVXMEBJLZRO-UHFFFAOYSA-N chlorthalidone Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C2(O)C3=CC=CC=C3C(=O)N2)=C1 JIVPVXMEBJLZRO-UHFFFAOYSA-N 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229960003176 cyclothiazide Drugs 0.000 description 1
- BOCUKUHCLICSIY-QJWLJZLASA-N cyclothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(S(N2)(=O)=O)=C1NC2C1[C@H](C=C2)C[C@H]2C1 BOCUKUHCLICSIY-QJWLJZLASA-N 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- AVOLMBLBETYQHX-UHFFFAOYSA-N etacrynic acid Chemical compound CCC(=C)C(=O)C1=CC=C(OCC(O)=O)C(Cl)=C1Cl AVOLMBLBETYQHX-UHFFFAOYSA-N 0.000 description 1
- 229960003199 etacrynic acid Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 229960003883 furosemide Drugs 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 150000002689 maleic acids Chemical class 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229960005483 polythiazide Drugs 0.000 description 1
- 229920000046 polythiazide Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- AGMMTXLNIQSRCG-UHFFFAOYSA-N quinethazone Chemical compound NS(=O)(=O)C1=C(Cl)C=C2NC(CC)NC(=O)C2=C1 AGMMTXLNIQSRCG-UHFFFAOYSA-N 0.000 description 1
- 229960000577 quinethazone Drugs 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid group Chemical group S(O)(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 229960004813 trichlormethiazide Drugs 0.000 description 1
- LMJSLTNSBFUCMU-UHFFFAOYSA-N trichlormethiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NC(C(Cl)Cl)NS2(=O)=O LMJSLTNSBFUCMU-UHFFFAOYSA-N 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH178579 | 1979-02-22 | ||
| CH178579A CH643457A5 (de) | 1979-02-22 | 1979-02-22 | Pharmazeutische praeparate zur behandlung der hypertonie. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NL8001000A true NL8001000A (nl) | 1980-08-26 |
Family
ID=4218544
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NL8001000A NL8001000A (nl) | 1979-02-22 | 1980-02-19 | Werkwijzen voor het bereiden van een geneesmiddel tegen hypertensie en voor het behandelen van hypertensie daarmede. |
Country Status (20)
| Country | Link |
|---|---|
| JP (1) | JPS55115823A (cs) |
| AT (1) | AT378915B (cs) |
| AU (1) | AU538599B2 (cs) |
| BE (1) | BE881763A (cs) |
| CA (1) | CA1147657A (cs) |
| CH (1) | CH643457A5 (cs) |
| DE (1) | DE3005029C2 (cs) |
| FR (1) | FR2449450A1 (cs) |
| GB (1) | GB2044101B (cs) |
| HU (1) | HU187271B (cs) |
| IE (1) | IE49073B1 (cs) |
| IL (1) | IL59432A (cs) |
| IT (1) | IT1145433B (cs) |
| MY (1) | MY8500619A (cs) |
| NL (1) | NL8001000A (cs) |
| NZ (1) | NZ192924A (cs) |
| PH (1) | PH17118A (cs) |
| PT (1) | PT70855A (cs) |
| SE (2) | SE8001121L (cs) |
| ZA (1) | ZA801018B (cs) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2537434A1 (fr) * | 1982-12-09 | 1984-06-15 | Sandoz Sa | Composition pharmaceutique d'endralazine sous forme retard |
| TW442301B (en) * | 1995-06-07 | 2001-06-23 | Sanofi Synthelabo | Pharmaceutical compositions containing irbesartan |
| GB2367242B (en) * | 2000-09-21 | 2004-07-28 | Henderson Morley Res & Dev Ltd | Antiviral treatment |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2458155A1 (de) * | 1973-12-19 | 1975-07-03 | Sandoz Ag | Neue pharmazeutische praeparate |
-
1979
- 1979-02-22 CH CH178579A patent/CH643457A5/de not_active IP Right Cessation
-
1980
- 1980-02-11 DE DE3005029A patent/DE3005029C2/de not_active Expired
- 1980-02-13 SE SE8001121A patent/SE8001121L/ not_active Application Discontinuation
- 1980-02-15 GB GB8005245A patent/GB2044101B/en not_active Expired
- 1980-02-18 BE BE1/9727A patent/BE881763A/fr not_active IP Right Cessation
- 1980-02-19 NL NL8001000A patent/NL8001000A/nl not_active Application Discontinuation
- 1980-02-20 AU AU55742/80A patent/AU538599B2/en not_active Ceased
- 1980-02-20 FR FR8003669A patent/FR2449450A1/fr active Granted
- 1980-02-20 NZ NZ192924A patent/NZ192924A/en unknown
- 1980-02-20 CA CA000346083A patent/CA1147657A/en not_active Expired
- 1980-02-20 IT IT47950/80A patent/IT1145433B/it active
- 1980-02-20 IE IE336/80A patent/IE49073B1/en unknown
- 1980-02-20 IL IL59432A patent/IL59432A/xx unknown
- 1980-02-20 PT PT70855A patent/PT70855A/pt unknown
- 1980-02-21 AT AT0095580A patent/AT378915B/de not_active IP Right Cessation
- 1980-02-21 PH PH23672A patent/PH17118A/en unknown
- 1980-02-21 JP JP1980480A patent/JPS55115823A/ja active Pending
- 1980-02-21 HU HU80402A patent/HU187271B/hu unknown
- 1980-02-22 ZA ZA00801018A patent/ZA801018B/xx unknown
-
1982
- 1982-04-15 SE SE8202357A patent/SE8202357L/xx not_active Application Discontinuation
-
1985
- 1985-12-30 MY MY619/85A patent/MY8500619A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IE49073B1 (en) | 1985-07-24 |
| IL59432A0 (en) | 1980-05-30 |
| PH17118A (en) | 1984-06-01 |
| SE8202357L (en) | 1982-04-15 |
| PT70855A (fr) | 1980-03-01 |
| CH643457A5 (de) | 1984-06-15 |
| GB2044101B (en) | 1983-09-07 |
| IE800336L (en) | 1980-08-22 |
| ZA801018B (en) | 1981-09-30 |
| SE8001121L (sv) | 1980-08-23 |
| NZ192924A (en) | 1984-05-31 |
| IT8047950A0 (it) | 1980-02-20 |
| DE3005029C2 (de) | 1987-02-12 |
| FR2449450B1 (cs) | 1983-07-22 |
| BE881763A (fr) | 1980-08-18 |
| IT1145433B (it) | 1986-11-05 |
| AU5574280A (en) | 1980-08-28 |
| IL59432A (en) | 1984-08-31 |
| FR2449450A1 (fr) | 1980-09-19 |
| ATA95580A (de) | 1985-03-15 |
| AU538599B2 (en) | 1984-08-23 |
| MY8500619A (en) | 1985-12-31 |
| CA1147657A (en) | 1983-06-07 |
| GB2044101A (en) | 1980-10-15 |
| AT378915B (de) | 1985-10-25 |
| HU187271B (en) | 1985-12-28 |
| JPS55115823A (en) | 1980-09-06 |
| DE3005029A1 (de) | 1980-09-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20100215737A1 (en) | Combination pharmaceutical compositions | |
| RU2292206C2 (ru) | Терапевтическая композиция амлодипина и беназеприла/беназеприлата | |
| AU2003229705A1 (en) | High drug load tablet | |
| HUT62488A (en) | Process for producing orally administrable pharmaceutical compositions comprising coagulation and platelet function inhibiting active ingredients in small dose | |
| US7135465B2 (en) | Sustained release beadlets containing stavudine | |
| RU2357757C2 (ru) | Твердый препарат | |
| JPH07504659A (ja) | Ａｃｅ阻害剤及び利尿剤の併用 | |
| KR20240108406A (ko) | 2'-데옥시시티딘 유사체를 포함하는 조성물 및 겸상 적혈구 질환, 지중해빈혈, 및 암의 치료를 위한 그의 용도 | |
| JP2002509540A (ja) | アルドースレダクターゼ阻害剤およびａｃｅ阻害剤を含有する医薬組成物 | |
| DE602004012763T2 (de) | Pharmazeutische zusammensetzung mit einem selektiven i1 imidazolin-rezeptor-agonisten und einem angiotensin-ii-rezeptorblocker | |
| NL8001000A (nl) | Werkwijzen voor het bereiden van een geneesmiddel tegen hypertensie en voor het behandelen van hypertensie daarmede. | |
| JP2002535367A (ja) | 急性心筋梗塞の処置のためのアンギオテンシンｉｉレセプターアンタゴニストの使用 | |
| KR20060109919A (ko) | 5-ｈｔ-수용체 아고니스트류를 위한 경구 제제들, 그들의용도 및 그들을 이용한 치료 방법 | |
| RU2182002C2 (ru) | Композиция с фиксированной дозой ингибитора ангиотензин-превращающего фермента и антагониста кальциевых каналов, способ ее изготовления и применение для лечения сердечно-сосудистых заболеваний | |
| CN105407876B (zh) | 抗结核病的稳定的包含异烟肼颗粒和利福喷汀颗粒的可分散的片剂及其制备方法 | |
| CA3182864A1 (en) | Methods and compositions for treating chemotherapy-induced diarrhea | |
| RU2206316C1 (ru) | Фармацевтическое средство сердечно-сосудистого действия | |
| GB2082910A (en) | Anti-depressant compositions | |
| WO2024047208A1 (en) | Anticoagulant therapy with an improved dosage regimen | |
| US20040138278A1 (en) | Use of AT1 receptor antagonists for prevention of subsequent strokes | |
| EP1004317A1 (en) | Remedies for diseases associated with bone resorption | |
| CZ301265B6 (cs) | Farmaceutický prípravek obsahující pentaerythrityltetra-, -tri-, -di- nebo -mononitrát, zpusob jeho prípravy a použití | |
| JPH04503806A (ja) | 治療剤 | |
| JP2004244347A (ja) | イトラコナゾール併用剤 | |
| NZ199783A (en) | Sustained release compositions containing endralazine embedded in a wax matrix |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| BT | A notification was added to the application dossier and made available to the public | ||
| BA | A request for search or an international-type search has been filed | ||
| BB | A search report has been drawn up | ||
| BC | A request for examination has been filed | ||
| A85 | Still pending on 85-01-01 | ||
| BV | The patent application has lapsed |